首页> 美国卫生研究院文献>Breast Cancer : Basic and Clinical Research >Breast Cancer Therapeutics and Biomarkers: Past Present and Future Approaches
【2h】

Breast Cancer Therapeutics and Biomarkers: Past Present and Future Approaches

机译:乳腺癌治疗和生物标志物:过去现在和未来的方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Breast cancer (BC) is the leading cause of cancer death in women and the second-most common cancer. An estimated 281 550 new cases of invasive BC will be diagnosed in women in the United States, and about 43 600 will die during 2021. Continual research has shed light on all disease areas, including tumor classification and biomarkers for diagnosis/prognosis. As research investigations evolve, new classes of drugs are emerging with potential benefits in BC treatment that are covered in this manuscript. The initial sections present updated classification and terminology used for diagnosis and prognosis, which leads to the following topics, discussing the past and present treatments available for BC. Our review will generate interest in exploring the complexity of the cell cycle and its association with cancer biology as part of the plethora of target factors toward developing newer drugs and effective therapeutic management of BC.
机译:乳腺癌(BC)是女性癌症死亡原因和第二次常见癌症。估计281 550新的侵袭性BC病例将被诊断出在美国的妇女中,大约43 00 600将在2021年期间死亡。持续研究在所有疾病领域都有光线,包括肿瘤分类和诊断/预后的生物标志物。随着研究调查的发展,新的药物在本手稿中涵盖的BC治疗中具有潜在的益处。初始部分存在用于诊断和预后的更新分类和术语,这导致以下主题,讨论了BC可用的过去和目前的治疗方法。我们的评论将产生兴趣探讨细胞周期的复杂性及其与癌症生物学的关联,作为朝向发展新药和BC有效治疗管理的目标因素的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号